The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23.
Navan, Inc.
NAVN · Nasdaq · USD · Market cap $7.0B · 3,700 employees
Navan, Inc.
PASS · Titan Ethical · score 70.0Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price25.42 USD at the 5 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 5 Nov 2026
- Our regime readAccumulation, as of 5 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.32)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $20.20 to $23.23, base estimate $20.20 (screen dated 2026-11-05).
- Trend Accumulation
- Insiders insiders sold, $209,942, latest filing 2026-11-02
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.32, read 2026-11-05
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Navan, Inc. holds its Accumulation at $25.42. Consolidating, no directional conviction, held for 27 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 27 days |
| Price at the screen | $25.42 |
| Valuation | N/A trailing · 67.61 forward price to earnings |
| Values screen | PASS · score 70.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.20% | Below 33% | Interest-bearing debt is just 10.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 9.19% | Below 33% | Cash held in interest-bearing accounts and securities is 9.2% of assets, under the one-third limit. | Pass |
| Receivables | 46.79% | Below 49% | Money owed to the company is 46.8% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.32% | Below 5% | Only 1.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Navan, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NAVN's ethical verdict changes
Today NAVN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $20.20 fair value estimate, 35.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 25.8% above the base estimate.
Third-party analyst targets. The average target sits +18% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $20.20, with a range of $20.20 to $23.23, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsAI travel app priced well beyond its worth
Picture a corporate traveller tapping an app to book a flight, only to watch the company burn cash on every trip while promising future magic from AI. Navan sits at this intersection, delivering 40% revenue growth through its expense platform yet posting a negative 47% profit margin and negative 53% return on equity. We pass because the current price of 25.96 dollars sits 26% above our fair value of 19.29 dollars, with a forward price to earnings ratio of 78.7 times that leaves no room for the execution slips common in this space.
The business model looks clean on paper and clears our ethical screen without issue, yet the unknown competitive moat and heavy losses make the growth story feel fragile rather than durable. Analyst targets cluster around 30 dollars on a strong buy consensus, but those figures ignore how quickly high multiples can compress when cash burn persists.
Risk sits around the valuation gap and the cyclical nature of corporate travel spend, where a slowdown could widen losses further and leave little buffer. Analysis, not advice.
| Forward P/E | 67.6xpriced for continued growth |
| EPS, trailing | -1.87 |
| EPS, forward | 0.40 |
| Revenue growth | +35.4%strong top-line growth |
| Profit margin | -42.1%currently unprofitable |
| Return on equity | -49.4%not currently earning a positive return on equity |
| FCF yield | 1.62% |
| Debt to equity | 0.13minimal debt: a conservative balance sheet |
| Current ratio | 4.38comfortably covers its short-term bills |
| Short interest, float | 0.36% |
| 52-week range | 8.11 - 30.88 |
| Market cap | $7.0B |
| Employees | 3,700 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNAVN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 34% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 26.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (15 analysts) rates it strong buy, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Navan Advances Open Model Strategy with NVIDIA to Deploy NVIDIA Nemotron 3.5 Super VL Yahoo Finance · 21d ago
- Navan Unveils New Ways to Book, Expense, and Travel at Navigate Europe 2026 Yahoo Finance · 22d ago
- Software stocks: Box and Navan lead after Citi investor meetings Yahoo Finance · 24d ago
- Wall Street Analysts See a 27.5% Upside in Navan (NAVN): Can the Stock Really Move This High? Yahoo Finance · 25d ago
- Navan Selected by Investec to Modernize Global Travel Program Yahoo Finance · 25d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-02 | Cohen Ariel M. | Chairperson, CEO | S - Sale | 8,033 | $209,942 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $18.26 | +13.6% | · | $1,136 | +13.6% |
| 2 months | $12.43 | +66.9% | · | $1,669 | +66.9% |
| 3 months | $8.88 | +133.7% | · | $2,337 | +133.7% |
| 6 months | $13.92 | +49.1% | · | $1,491 | +49.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NAVN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.